Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Literature for peptidase S01.231: urokinase-type plasminogen activator

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: A Assay, S Structure, T Target, K Knockout, P Specificity, E Expression, V Review, M Mutation, I Inhibitor, L Localization, U Therapeutic. To select only the references relevant to a single topic, click the link above. See explanation.)

    2025
  1. Hu,K., Wang,X., Dai,D., Shen,J., Zhang,S., Ohkubo,T., Xie,L., Zhang,Y., Li,G., Liu,C., Tian,H., Zhang,Y., Zhang,M.R. and Wang,R.
    A Cyclic Peptide-Based Radiotheranostic Agent for Urokinase-Type Plasminogen Activator in Tumors
    Chemistrye202500479-e202500479. PubMed  Europe PubMed DOI
    2. 2024
  2. Torres-Paris,C., Song,H.J., Engelberger,F., Ramirez-Sarmiento,C.A. and Komives,E.A.
    The Light Chain Allosterically Enhances the Protease Activity of Murine Urokinase-Type Plasminogen Activator
    Biochemistry63, 1434-1444. PubMed  Europe PubMed DOI
    3. 2023
  3. Alfieri,M., Meo,L. and Ragno,P.
    Posttranscriptional Regulation of the Plasminogen Activation System by Non-Coding RNA in Cancer
    Int J Mol Sci24, PubMed  Europe PubMed DOI  V
  4. Hu,X., Sun,X., Liu,X., Xu,H.D., Yang,L., Liu,S., Wang,R. and Liang,G.
    Enhanced Photoacoustic Imaging of Urokinase-Type Plasminogen Activator Activity in Tumors
    Anal Chem95, 14511-14515. PubMed  Europe PubMed DOI
  5. Kanno,Y.
    The uPA/uPAR System Orchestrates the Inflammatory Response, Vascular Homeostasis, and Immune System in Fibrosis Progression
    Int J Mol Sci24, PubMed  Europe PubMed DOI  V
  6. Kondo,Y., Rajapakse,S. and Ogiwara,K.
    Involvement of cathepsin L in the degradation and degeneration of postovulatory follicle of the medaka ovarydagger
    Biol Reprod109, 904-917. PubMed  Europe PubMed DOI
  7. Mazzocato,Y., Perin,S., Morales-Sanfrutos,J., Romanyuk,Z., Pluda,S., Acquasaliente,L., Borsato,G., De Filippis,V., Scarso,A. and Angelini,A.
    A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue
    Bioorg Med Chem95, 117499-117499. PubMed  Europe PubMed DOI  I
  8. Micalet,A., Tappouni,L.J., Peszko,K., Karagianni,D., Lam,A., Counsell,J.R., Quezada,S.A., Moeendarbary,E. and Cheema,U.
    Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer
    Matrix Biol Plus19-20, 100137-100137. PubMed  Europe PubMed DOI
  9. Tan,J., Ge,Y., Zhang,M. and Ding,M.
    Proteomics analysis uncovers plasminogen activator PLAU as a target of the STING pathway for suppression of cancer cell migration and invasion
    J Biol Chem299, 102779-102779. PubMed  Europe PubMed DOI
  10. Torres-Paris,C., Chen,Y., Xiao,L., Song,H.J., Chen,P. and Komives,E.A.
    The autoactivation of human single-chain urokinase-type plasminogen activator (uPA)
    J Biol Chem299, 105179-105179. PubMed  Europe PubMed DOI
    11. 2022
  11. Arancillo,M., Lin,C.M. and Burgess,K.
    Piptide Chemotypes for Perturbation of the Interaction of Urokinase with Its Receptor
    J Med Chem65, 12925-12932. PubMed  Europe PubMed DOI
  12. Cheung,E.Y.H., Chan,D.Y.C., Lee,M.W.Y., Hung,C.Y. and Pang,K.Y.
    Urokinase Is Safe and Effective in Reducing Recurrence in Chronic Subdural Hematoma After Burr-Hole Drainage
    World Neurosurg164, e1209-e1209. PubMed  Europe PubMed DOI
  13. Diaz,A., Martin-Jimenez,C., Woo,Y., Merino,P., Torre,E. and Yepes,M.
    Urokinase-Type Plasminogen Activator Triggers Wingless/Int1-Independent Phosphorylation of the Low-Density Lipoprotein Receptor-Related Protein-6 in Cerebral Cortical Neurons
    J Alzheimers Dis89, 877-891. PubMed  Europe PubMed DOI
  14. Dreymann,N., Wuensche,J., Sabrowski,W., Moeller,A., Czepluch,D., Vu Van,D., Fuessel,S. and Menger,M.M.
    Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA
    Int J Mol Sci23, PubMed  Europe PubMed DOI
  15. El Salamouni,N.S., Buckley,B.J., Ranson,M., Kelso,M.J. and Yu,H.
    Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity
    Biophys Rev14, 277-301. PubMed  Europe PubMed DOI  V
  16. Ganguly,R., Mylliemngap,B.J. and Bhattacharjee,A.
    Discovery of a novel inhibitor against urokinase-type plasminogen activator, a potential enzyme with a role in atherosclerotic plaque instability
    J Biomol Struct Dyn1-11. PubMed  Europe PubMed DOI
  17. Gao,C., Tang,S., Zhang,H., Zhang,H., Zhang,T., Bao,B., Zhu,Y. and Wu,W.
    A Novel Marine Pyran-Isoindolone Compound Enhances Fibrin Lysis Mediated by Single-Chain Urokinase-Type Plasminogen Activator
    Mar Drugs20, PubMed  Europe PubMed DOI
  18. Mehner,C., Hockla,A., Coban,M., Madden,B., Estrada,R., Radisky,D.C. and Radisky,E.S.
    Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma
    J Biol Chem298, 102146-102146. PubMed  Europe PubMed DOI
  19. Moro,G., Severin Sfragano,P., Ghirardo,J., Mazzocato,Y., Angelini,A., Palchetti,I. and Polo,F.
    Bicyclic peptide-based assay for uPA cancer biomarker
    Biosens Bioelectron213, 114477-114477. PubMed  Europe PubMed DOI
  20. Tagirasa,R. and Yoo,E.
    Role of Serine Proteases at the Tumor-Stroma Interface
    Front Immunol13, 832418-832418. PubMed  Europe PubMed DOI  V
  21. Yepes,M.
    The uPA/uPAR system in astrocytic wound healing
    Neural Regen Res17, 2404-2406. PubMed  Europe PubMed DOI
  22. Zhou,Y., Wu,J., Xue,G., Li,J., Jiang,L. and Huang,M.
    Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat
    Biophys J121, 3940-3949. PubMed  Europe PubMed DOI  I
  23. Zhu,R., Liu,T.W. and Liu,F.
    Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
    Front Pharmacol13, 754271-754271. PubMed  Europe PubMed DOI
    24. 2021
  24. Bum-Erdene,K., Liu,D., Xu,D., Ghozayel,M.K. and Meroueh,S.O.
    Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR.uPA Interaction
    ACS Med Chem Lett12, 60-66. PubMed  Europe PubMed DOI
  25. Diaz,A., Martin-Jimenez,C., Xu,Y., Merino,P., Woo,Y., Torre,E. and Yepes,M.
    Urokinase-type plasminogen activator-mediated crosstalk between N-cadherin and beta-Catenin promotes wound healing
    J Cell Sci PubMed  Europe PubMed DOI
  26. Ismail,A.A., Shaker,B.T. and Bajou,K.
    The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis
    Int J Mol Sci23, PubMed  Europe PubMed DOI
  27. Kryza,T., Khan,T., Lovell,S., Harrington,B.S., Yin,J., Porazinski,S., Pajic,M., Koistinen,H., Rantala,J.K., Dreyer,T., Magdolen,V., Reuning,U., He,Y., Tate,E.W. and Hooper,J.D.
    Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1
    Nat Chem Biol PubMed  Europe PubMed DOI
  28. Salamouni,S.E., Buckley,B.J., Jiang,L., Huang,M., Ranson,M., Kelso,M.J. and Yu,H.
    Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA)
    J Med Chem PubMed  Europe PubMed DOI
  29. Tucker,T.A. and Idell,S.
    The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
    Int J Mol Sci22, PubMed  Europe PubMed DOI  V
  30. Vorstandlechner,V., Laggner,M., Copic,D., Klas,K., Direder,M., Chen,Y., Golabi,B., Haslik,W., Radtke,C., Tschachler,E., Hotzenecker,K., Ankersmit,H.J. and Mildner,M.
    The serine proteases dipeptidyl-peptidase 4 and urokinase are key molecules in human and mouse scar formation
    Nat Commun12, 6242-6242. PubMed  Europe PubMed DOI
    31. 2020
  31. Almholt,K., Wang,J., Pass,J., Roder,G., Padkjaer,S.B., Hebsgaard,J.B., Xia,W., Yang,L., Forsell,J., Breinholt,V.M., Thygesen,P., Agerso,H., Loftager,M. and Usher,P.A.
    Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis
    J Mol Med (Berl)98, 585-593. PubMed  Europe PubMed DOI  U
  32. Belfiore,L., Saunders,D.N., Ranson,M. and Vine,K.L.
    N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer
    Pharmaceutics12, PubMed  Europe PubMed DOI
  33. Brunet,J.G., Sharma,T., Tasneem,S., Liang,M., Wilson,M.D., Rivard,G.E. and Hayward,C.P.M.
    Thrombin generation abnormalities in Quebec platelet disorder
    Int J Lab Hematole13302-e13302. PubMed  Europe PubMed DOI  I
  34. Joossen,C., Baan,A., Moreno-Cinos,C., Joossens,J., Cools,N., Lanckacker,E., Moons,L., Lemmens,K., Lambeir,A.M., Fransen,E., Delputte,P., Caljon,G., Van der Veken,P., Maes,L., De Meester,I., Kiekens,F., Augustyns,K. and Cos,P.
    A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation
    Sci Rep10, 17268-17268. PubMed  Europe PubMed DOI  I
  35. Nassir,A.M. and Kamel,H.F.M.
    Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4-10 ng/mL
    Saudi J Biol Sci27, 1975-1984. PubMed  Europe PubMed DOI
  36. Pulukuri,S.M.K., Gorantla,B. and Rao,J.S.
    Retraction: Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator
    J Biol Chem295, 13407-13407. PubMed  Europe PubMed DOI
  37. Sevillano,N., Bohn,M.F., Zimanyi,M., Chen,Y., Petzold,C., Gupta,S., Ralston,C.Y. and Craik,C.S.
    Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity
    Biochim Biophys Acta Proteins Proteom1869, 140562-140562. PubMed  Europe PubMed DOI
  38. Westrick,R.J., Rojkjaer,L.P., Yang,A.Y., Roh,M.H., Siebert,A.E. and Ginsburg,D.
    Deficiency of Plasminogen Activator Inhibitor-2 Results in Accelerated Tumor Growth
    J Thromb Haemost18, 2968-2975. PubMed  Europe PubMed DOI
  39. Yang,B., Zhang,D., Qian,J. and Cheng,Y.
    Chelerythrine suppresses proliferation and metastasis of human prostate cancer cells via modulating MMP/TIMP/NF-kappaB system
    Mol Cell Biochem474, 199-208. PubMed  Europe PubMed DOI
    40. 2019
  40. Buckley,B.J., Majed,H., Aboelela,A., Minaei,E., Jiang,L., Fildes,K., Cheung,C.Y., Johnson,D., Bachovchin,D., Cook,G.M., Huang,M., Ranson,M. and Kelso,M.J.
    6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease
    Bioorg Med Chem Lett126753-126753. PubMed  Europe PubMed DOI  S  I
  41. Chana-Munoz,A., Jendroszek,A., Sonnichsen,M., Wang,T., Ploug,M., Jensen,J.K., Andreasen,P.A., Bendixen,C. and Panitz,F.
    Origin and diversification of the plasminogen activation system among chordates
    BMC Evol Biol19, 27-27. PubMed  Europe PubMed DOI
  42. Jendroszek,A., Madsen,J.B., Chana-Munoz,A., Dupont,D.M., Christensen,A., Panitz,F., Fuchtbauer,E.M., Lovell,S.C. and Jensen,J.K.
    Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors
    J Biol Chem294, 3794-3805. PubMed  Europe PubMed DOI
  43. Li,C.Y., de Veer,S.J., Law,R.H.P., Whisstock,J.C., Craik,D.J. and Swedberg,J.E.
    Characterising the subsite specificity of urokinase-type plasminogen activator and tissue-type plasminogen activator using a sequence-defined peptide aldehyde library
    Chembiochem20, 46-50. PubMed  Europe PubMed DOI  P  I
  44. Wang,D., Yang,Y., Jiang,L., Wang,Y., Li,J., Andreasen,P.A., Chen,Z., Huang,M. and Xu,P.
    Suppression of tumor growth and metastases by targeted intervention in urokinase activity with cyclic peptides
    J Med Chem62, 2172-2183. PubMed  Europe PubMed DOI  I
  45. Wu,G., Mazzitelli,B.A., Quek,A.J., Veldman,M.J., Conroy,P.J., Caradoc-Davies,T.T., Ooms,L.M., Tuck,K.L., Schoenecker,J.G., Whisstock,J.C. and Law,R.H.P.
    Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
    Blood Adv3, 729-733. PubMed  Europe PubMed DOI  I
    46. 2018
  46. Almholt,K., Hebsgaard,J.B., Nansen,A., Andersson,C., Pass,J., Rono,B., Thygesen,P., Pelzer,H., Loftager,M., Lund,I.K., Hoyer-Hansen,G., Frisch,T., Jensen,C.H., Otte,K.S., Soe,N.H., Bartels,E.M., Andersen,M., Bliddal,H. and Usher,P.A.
    Antibody-mediated neutralization of uPA proteolytic function reduces disease progression in mouse arthritis models
    J Immunol200, 957-965. PubMed  Europe PubMed DOI
  47. Buckley,B.J., Aboelela,A., Minaei,E., Jiang,L.X., Xu,Z., Ali,U., Fildes,K., Cheung,C.Y., Cook,S.M., Johnson,D.C., Bachovchin,D.A., Cook,G.M., Apte,M., Huang,M., Ranson,M. and Kelso,M.J.
    6-Substituted hexamethylene amiloride (HMA) derivatives as potent and selective inhibitors of the human urokinase plasminogen activator for use in cancer
    J Med Chem61, 8299-8320. PubMed  Europe PubMed DOI  I
  48. Ding,X., Li,H., Li,Y., Huang,D. and Xiong,C.
    Two B-cell epitope vaccines based on uPA effectively inhibit fertility in male mice
    Vaccine36, 2612-2618. PubMed  Europe PubMed DOI
  49. Islam,I., Yuan,S., West,C.W., Adler,M., Bothe,U., Bryant,J., Chang,Z., Chu,K., Emayan,K., Gualtieri,G., Ho,E., Light,D., Mallari,C., Morser,J., Phillips,G., Schaefer,C., Sukovich,D., Whitlow,M., Chen,D. and Buckman,B.O.
    Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis
    Bioorg Med Chem Lett28, 3372-3375. PubMed  Europe PubMed DOI  I
  50. Merino,P. and Yepes,M.
    Urokinase-type plasminogen activator induces neurorepair in the ischemic brain
    J Neurol Exp Neurosci4, 24-29. PubMed  Europe PubMed DOI
  51. Solis-Calero,C., Zanatta,G., Pessoa,C.D.O., Carvalho,H.F. and Freire,V.N.
    Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry
    Phys Chem Chem Phys20, 22818-22830. PubMed  Europe PubMed DOI  I
    52. 2017
  52. Cerisier,N., Regad,L., Triki,D., Camproux,A.C. and Petitjean,M.
    Cavity versus ligand shape descriptors: application to urokinase binding pockets
    J Comput Biol24, 1134-1137. PubMed  Europe PubMed DOI
  53. Kromann-Hansen,T., Louise Lange,E., Peter Sorensen,H., Hassanzadeh-Ghassabeh,G., Huang,M., Jensen,J.K., Muyldermans,S., Declerck,P.J., Komives,E.A. and Andreasen,P.A.
    Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator
    Sci Rep7, 3385-3385. PubMed  Europe PubMed DOI
  54. Tan,Q., Chen,Q., Niu,Y., Feng,Z., Li,L., Tao,Y., Tang,J., Yang,L., Guo,J., Feng,H., Zhu,G. and Chen,Z.
    Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage
    J Neurosurg126, 548-557. PubMed  Europe PubMed DOI
  55. Xue,G., Gong,L., Yuan,C., Xu,M., Wang,X., Jiang,L. and Huang,M.
    A structural mechanism of flavonoids in inhibiting serine proteases
    Food Funct8, 2437-2443. PubMed  Europe PubMed DOI  S  I
  56. Zhao,K., Liu,Y., Xiong,Z., Hu,L. and Xiong,C.L.
    Tissue-specific inhibition of urokinase-type plasminogen activator expression in the testes of mice by inducible lentiviral RNA interference causes male infertility
    Reprod Fertil Dev29, 2149-2156. PubMed  Europe PubMed DOI  K
    57. 2016
  57. Dupont,D.M., Bjerregaard,N., Verpaalen,B., Andreasen,P.A. and Jensen,J.K.
    Building a molecular trap for a serine protease from aptamer and peptide modules
    Bioconjug Chem27, 918-926. PubMed  Europe PubMed DOI
  58. Gong,L., Proulle,V., Fang,C., Hong,Z., Lin,Z., Liu,M., Xue,G., Yuan,C., Lin,L., Furie,B., Flaumenhaft,R., Andreasen,P., Furie,B. and Huang,M.
    A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase
    J Cell Mol Med20, 1851-1860. PubMed  Europe PubMed DOI
  59. Jiang,L., Andersen,L.M., Andreasen,P.A., Chen,L. and Huang,M.
    Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate
    Biochim Biophys Acta1860, 599-606. PubMed  Europe PubMed DOI  S  I
  60. Maleki,A., Tohidi-Zand,S.R., Amirizadeh,N., Dehghan-Haghighi,J., Zanjani,H., Arish,M., Salari,A.M., Mirhosseini,S.M. and Abrishami,M.
    Intravitreal autologous plasmin prepared by urokinase for vitreolysis: a pilot study
    Eur J Ophthalmol26, 67-70. PubMed  Europe PubMed DOI
    61. 2015
  61. Beloglazova,I.B., Plekhanova,O.S., Katkova,E.V., Rysenkova,K.D., Stambol'skii,D.V., Sulimov,V.B. and Tkachuk,V.A.
    Molecular modeling as a new approach to the development of urokinase inhibitors
    Bull Exp Biol Med158, 700-704. PubMed  Europe PubMed DOI  I
  62. Fasoli,E., Righetti,P.G., Moltrasio,D. and D'Amato,A.
    Extensive heterogeneity of human urokinase, as detected by two-dimensional mapping
    Anal Chem87, 1509-1513. PubMed  Europe PubMed DOI
  63. Gladysz,R., Adriaenssens,Y., De Winter,H., Joossens,J., Lambeir,A.M., Augustyns,K. and Van der Veken,P.
    Discovery and SAR of novel and selective inhibitors of urokinase plasminogen activator (uPA) with an imidazo[1,2-a]pyridine scaffold
    J Med Chem58, 9238-9257. PubMed  Europe PubMed DOI  I
  64. Jiang,L., Zhao,B., Xu,P., Sorensen,H.P., Jensen,J.K., Christensen,A., Hosseini,M., Nielsen,N.C., Jensen,K.J., Andreasen,P.A. and Huang,M.
    Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues
    Int J Biochem Cell Biol62, 88-92. PubMed  Europe PubMed DOI  I
  65. Lebeau,A.M., Sevillano,N., Markham,K., Winter,M.B., Murphy,S.T., Hostetter,D.R., West,J., Lowman,H., Craik,C.S. and Vanbrocklin,H.F.
    Imaging active urokinase plasminogen activator in prostate cancer
    Cancer Res75, 1225-1235. PubMed  Europe PubMed DOI  L
  66. Qin,Y., Han,Y., Xiong,C.L., Li,H.G., Hu,L. and Zhang,L.
    Urokinase-type plasminogen activator: a new target for male contraception?
    Asian J Androl17, 269-273. PubMed  Europe PubMed DOI
  67. Sorensen,H.P., Xu,P., Jiang,L., Kromann-Hansen,T., Jensen,K.J., Huang,M. and Andreasen,P.A.
    Selection of high-affinity peptidic serine protease inhibitors with increased binding entropy from a back-flip library of peptide-protease fusions
    J Mol Biol427, 3110-3122. PubMed  Europe PubMed DOI  I
    68. 2014
  68. Faid,V., Denguir,N., Chapuis,V., Bihoreau,N. and Chevreux,G.
    Site-specific N-glycosylation analysis of human factor XI: identification of a noncanonical NXC glycosite
    Proteomics14, 2460-2470. PubMed  Europe PubMed DOI
  69. Mekkawy,A.H., Pourgholami,M.H. and Morris,D.L.
    Involvement of urokinase-type plasminogen activator system in cancer: an overview
    Med Res Rev34, 918-956. PubMed  Europe PubMed DOI  V
  70. Popa,N.L., Wergedal,J.E., Lau,K.H., Mohan,S. and Rundle,C.H.
    Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling
    J Bone Miner Metab32, 124-135. PubMed  Europe PubMed DOI  K
  71. Sulimov,V.B., Katkova,E.V., Oferkin,I.V., Sulimov,A.V., Romanov,A.N., Roschin,A.I., Beloglazova,I.B., Plekhanova,O.S., Tkachuk,V.A. and Sadovnichiy,V.A.
    Application of molecular modeling to urokinase inhibitors development
    Biomed Res Int2014, 625176-625176. PubMed  Europe PubMed DOI  I
  72. Zhao,B., Xu,P., Jiang,L., Paaske,B., Kromann-Hansen,T., Jensen,J.K., Sorensen,H.P., Liu,Z., Nielsen,J.T., Christensen,A., Hosseini,M., Sorensen,K.K., Nielsen,N.C., Jensen,K.J., Huang,M. and Andreasen,P.A.
    A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility
    PLoS ONE9, e115872-e115872. PubMed  Europe PubMed DOI  S  I
    73. 2013
  73. Chen,S., Gfeller,D., Buth,S.A., Michielin,O., Leiman,P.G. and Heinis,C.
    Improving binding affinity and stability of peptide ligands by substituting glycines with d-amino acids
    Chembiochem14, 1316-1322. PubMed  Europe PubMed DOI  I
  74. Fasoli,E., Reyes,Y.R., Guzman,O.M., Rosado,A., Cruz,V.R., Borges,A., Martinez,E. and Bansal,V.
    Para-aminobenzamidine linked regenerated cellulose membranes for plasminogen activator purification: Effect of spacer arm length and ligand density
    J Chromatogr B Analyt Technol Biomed Life Sci930, 13-21. PubMed  Europe PubMed DOI  I
  75. Ichimura,A., Matsumoto,S., Suzuki,S., Dan,T., Yamaki,S., Sato,Y., Kiyomoto,H., Ishii,N., Okada,K., Matsuo,O., Hou,F.F., Vaughan,D.E., van Ypersele de Strihou,C. and Miyata,T.
    A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration
    Arterioscler Thromb Vasc Biol33, 935-942. PubMed  Europe PubMed DOI  I
  76. Jarvinen,H.M., Laakkonen,L., Haiko,J., Johansson,T., Juuti,K., Suomalainen,M., Buchrieser,C., Kalkkinen,N. and Korhonen,T.K.
    Human single-chain urokinase is activated by the omptins PgtE of Salmonella enterica and Pla of Yersinia pestis despite mutations of active site residues
    Mol Microbiol89, 507-517. PubMed  Europe PubMed DOI
  77. Jiang,L., Botkjaer,K.A., Andersen,L.M., Yuan,C., Andreasen,P.A. and Huang,M.
    Rezymogenation of active urokinase induced by an inhibitory antibody
    Biochem J449, 161-166. PubMed  Europe PubMed DOI
  78. Kromann-Hansen,T., Lund,I.K., Liu,Z., Andreasen,P.A., Hoyer-Hansen,G. and Sorensen,H.P.
    Allosteric inactivation of a trypsin-like serine protease by an antibody binding to the 37- and 70-loops
    Biochemistry52, 7114-7126. PubMed  Europe PubMed DOI
  79. Lee,S.H., Gupta,M.K., Ho,Y.T., Kim,T. and Lee,H.T.
    Transgenic chickens expressing human urokinase-type plasminogen activator
    Poult Sci92, 2396-2403. PubMed  Europe PubMed DOI  E
  80. Li,J., Lin,Y., Zhuang,H. and Hua,Z.C.
    Expression, purification, and biological characterization of the amino-terminal fragment of urokinase in Pichia pastoris
    J Microbiol Biotechnol23, 1197-1205. PubMed  Europe PubMed DOI  E
  81. Montuori,N., Cosimato,V., Rinaldi,L., Rea,V.E., Alfano,D. and Ragno,P.
    uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors
    Thromb Haemost109, 309-318. PubMed  Europe PubMed DOI
  82. Rao Malla,R., Gopinath,S., Alapati,K., Gorantla,B., Gondi,C.S. and Rao,J.S.
    Knockdown of cathepsin B and uPAR inhibits CD151 and alpha3beta1 integrin-mediated cell adhesion and invasion in glioma
    Mol Carcinog52, 777-790. PubMed  Europe PubMed DOI  K
  83. Roodbeen,R., Paaske,B., Jiang,L., Jensen,J.K., Christensen,A., Nielsen,J.T., Huang,M., Mulder,F.A., Nielsen,N.C., Andreasen,P.A. and Jensen,K.J.
    Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action
    Chembiochem14, 2179-2188. PubMed  Europe PubMed DOI  I
    84. 2012
  84. Bhongade,B.A., Amnerkar,N.D., Talath,S., Bhusari,K.P. and Gadad,A.K.
    3D-QSAR studies on isocoumarin-based urokinase-type plasminogen activator (uPA) inhibitors employing linear and non-linear regression analysis methods
    Lett Drug Des Discov9, 874-880.  I
  85. Botkjaer,K.A., Deryugina,E.I., Dupont,D.M., Gardsvoll,H., Bekes,E.M., Thuesen,C.K., Chen,Z., Ploug,M., Quigley,J.P. and Andreasen,P.A.
    Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism
    Mol Cancer Res10, 1532-1543. PubMed  Europe PubMed DOI  I
  86. Ellis,V.
    u-Plasminogen activator
    [ISSN:978-0-12-407742-3]3, 2938-2945. DOI
  87. Jakobsche,C.E., McEnaney,P.J., Zhang,A.X. and Spiegel,D.A.
    Reprogramming urokinase into an antibody-recruiting anticancer agent
    ACS Chem Biol7, 316-321. PubMed  Europe PubMed DOI  U
  88. Kawao,N., Nagai,N., Tamura,Y., Horiuchi,Y., Okumoto,K., Okada,K., Suzuki,Y., Umemura,K., Yano,M., Ueshima,S., Kaji,H. and Matsuo,O.
    Urokinase-type plasminogen activator and plasminogen mediate activation of macrophage phagocytosis during liver repair in vivo
    Thromb Haemost107, 749-759. PubMed  Europe PubMed DOI  K
  89. Liu,Z., Kromann-Hansen,T., Lund,I.K., Hosseini,M., Jensen,K.J., Hoyer-Hansen,G., Andreasen,P.A. and Sorensen,H.P.
    Interconversion of active and inactive conformations of urokinase-type plasminogen activator
    Biochemistry51, 7804-7811. PubMed  Europe PubMed DOI  I
  90. Massey,A.P., Harley,W.R., Pasupuleti,N., Gorin,F.A. and Nantz,M.H.
    2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator
    Bioorg Med Chem Lett22, 2635-2639. PubMed  Europe PubMed DOI  I
  91. Venkatraj,M., Messagie,J., Joossens,J., Lambeir,A.M., Haemers,A., Van der Veken,P. and Augustyns,K.
    Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA)
    Bioorg Med Chem20, 1557-1568. PubMed  Europe PubMed DOI  I
    92. 2011
  92. Behrens,M.A., Botkjaer,K.A., Goswami,S., Oliveira,C.L., Jensen,J.K., Schar,C.R., Declerck,P.J., Peterson,C.B., Andreasen,P.A. and Pedersen,J.S.
    Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility
    J Mol Biol411, 417-429. PubMed  Europe PubMed DOI
  93. Carriero,M.V., Franco,P., Votta,G., Longanesi-Cattani,I., Vento,M.T., Masucci,M.T., Mancini,A., Caputi,M., Iaccarino,I. and Stoppelli,M.P.
    Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors
    Curr Drug Targets12, 1761-1771. PubMed  Europe PubMed DOI
  94. Carriero,M.V. and Stoppelli,M.P.
    The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling
    Curr Pharm Des17, 1944-1961. PubMed  Europe PubMed DOI  V
  95. Hosseini,M., Jiang,L., Sorensen,H.P., Jensen,J.K., Christensen,A., Fogh,S., Yuan,C., Andersen,L.M., Huang,M., Andreasen,P.A. and Jensen,K.J.
    Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs
    Mol Pharmacol80, 585-597. PubMed  Europe PubMed DOI  I
  96. Lin,Z., Jiang,L., Yuan,C., Jensen,J.K., Zhang,X., Luo,Z., Furie,B.C., Furie,B., Andreasen,P.A. and Huang,M.
    Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1
    J Biol Chem286, 7027-7032. PubMed  Europe PubMed DOI
  97. Liu,J., Wang,Y., Yang,Y., Jiang,X., Zhao,M., Wang,W., Wu,G., Wu,J., Zheng,M. and Peng,S.
    Pyrolo[1,2:4,5]-1,4-dioxopyrazino[1,2:1,6]pyrido[3,4-b]indoles: a group of urokinase inhibitors, their synthesis, and stereochemistry-dependent activity
    ChemMedChem6, 2312-2322. PubMed  Europe PubMed DOI  I
  98. Malik,R., Qian,S. and Law,B.
    Design and synthesis of a near-infrared fluorescent nanofiber precursor for detecting cell-secreted urokinase activity
    Anal Biochem412, 26-33. PubMed  Europe PubMed DOI  A
  99. Mei,S., Liu,J., Zhao,M., Wang,W., Wang,Y., Wu,G., Zheng,M. and Peng,S.
    From Cerius2 based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors
    Mol Biosyst7, 2664-2669. PubMed  Europe PubMed DOI  I
  100. Venkatraman,L., Li,H., Dewey,C.F., Jr., White,J.K., Bhowmick,S.S., Yu,H. and Tucker-Kellogg,L.
    Steady states and dynamics of urokinase-mediated plasmin activation in silico and in vitro
    Biophys J101, 1825-1834. PubMed  Europe PubMed DOI
    101. 2010
  101. Davami,F., Sardari,S., Majidzadeh,A., Hemayatkar,M., Barkhrdari,F., Omidi,M., Azami,M., Adeli,A., Davoudi,N. and Mahboudi,F.
    Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments
    J Biomed Biotechnol2010, 108159-108159. PubMed  Europe PubMed DOI  E
  102. David,H.N., Haelewyn,B., Risso,J.J., Colloc'h,N. and Abraini,J.H.
    Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke
    J Cereb Blood Flow Metab30, 718-728. PubMed  Europe PubMed DOI  I
  103. Henneke,I., Greschus,S., Savai,R., Korfei,M., Markart,P., Mahavadi,P., Schermuly,R.T., Wygrecka,M., Sturzebecher,J., Seeger,W., Gunther,A. and Ruppert,C.
    Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model
    Am J Respir Crit Care Med181, 611-619. PubMed  Europe PubMed DOI  I
  104. Jogi,A., Rono,B., Lund,I.K., Nielsen,B.S., Ploug,M., Hoyer-Hansen,G., Romer,J. and Lund,L.R.
    Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice
    PLoS ONE5, e12746-e12746. PubMed  Europe PubMed DOI  K
  105. Paterson,A.D., Rommens,J.M., Bharaj,B., Blavignac,J., Wong,I., Diamandis,M., Waye,J.S., Rivard,G.E. and Hayward,C.P.
    Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene
    Blood115, 1264-1266. PubMed  Europe PubMed DOI  M
  106. Sgier,D., Zuberbuehler,K., Pfaffen,S. and Neri,D.
    Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA
    Protein Eng Des Sel23, 261-269. PubMed  Europe PubMed DOI
    107. 2009
  107. Botkjaer,K.A., Byszuk,A.A., Andersen,L.M., Christensen,A., Andreasen,P.A. and Blouse,G.E.
    Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides
    Biochemistry48, 9606-9617. PubMed  Europe PubMed DOI
  108. Gurewich,V. and Pannell,R.
    Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis
    Thromb Haemost102, 279-286. PubMed  Europe PubMed DOI
  109. Jiang,L.G., Zhao,G.X., Bian,C.B., Yuan,C., Huang,Z.X. and Huang,M.D.
    Crystal structures of urokinase-type plasminogen activator in complex with 4-(aminomethyl)benzoic acid and 4-(aminomethyl-phenyl)-methanol
    Jiegou Huaxue28, 253-259.  S  I
  110. Karthikeyan,C., Moorthy,N.S. and Trivedi,P.
    QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors
    J Enzyme Inhib Med Chem24, 6-13. PubMed  Europe PubMed DOI  I
  111. Ulisse,S., Baldini,E., Sorrenti,S. and D'Armiento,M.
    The urokinase plasminogen activator system: a target for anti-cancer therapy
    Curr Cancer Drug Targets9, 32-71. PubMed  Europe PubMed DOI  T
  112. West,C.W., Adler,M., Arnaiz,D., Chen,D., Chu,K., Gualtieri,G., Ho,E., Huwe,C., Light,D., Phillips,G., Pulk,R., Sukovich,D., Whitlow,M., Yuan,S. and Bryant,J.
    Identification of orally bioavailable, non-amidine inhibitors of urokinase plasminogen activator (uPA)
    Bioorg Med Chem Lett19, 5712-5715. PubMed  Europe PubMed DOI  I
    113. 2008
  113. Andersen,L.M., Wind,T., Hansen,H.D. and Andreasen,P.A.
    A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue
    Biochem J412, 447-457. PubMed  Europe PubMed DOI  I
  114. Frederickson,M., Callaghan,O., Chessari,G., Congreve,M., Cowan,S.R., Matthews,J.E., McMenamin,R., Smith,D.M., Vinkovic,M. and Wallis,N.G.
    Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator
    J Med Chem51, 183-186. PubMed  Europe PubMed DOI  I
  115. Killeen,S., Hennessey,A., El Hassan,Y. and Waldron,B.
    The urokinase plasminogen activator system in cancer: a putative therapeutic target?
    Drug News Perspect21, 107-116. PubMed  Europe PubMed DOI  V  T
    116. 2007
  116. Crippa,M.P.
    Urokinase-type plasminogen activator
    Int J Biochem Cell Biol39, 690-694. PubMed  Europe PubMed DOI  V
  117. Fish,P.V., Barber,C.G., Brown,D.G., Butt,R., Collis,M.G., Dickinson,R.P., Henry,B.T., Horne,V.A., Huggins,J.P., King,E., O'Gara,M., McCleverty,D., McIntosh,F., Phillips,C. and Webster,R.
    Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines
    J Med Chem50, 2341-2351. PubMed  Europe PubMed DOI  I
  118. Grzywa,R., Dyguda-Kazimierowicz,E., Sienczyk,M., Feliks,M., Sokalski,W.A. and Oleksyszyn,J.
    The molecular basis of urokinase inhibition: from the nonempirical analysis of intermolecular interactions to the prediction of binding affinity
    J Mol Model13, 677-683. PubMed  Europe PubMed DOI  I
  119. Joossens,J., Ali,O.M., El-Sayed,I., Surpateanu,G., Van der Veken,P., Lambeir,A.M., Setyono-Han,B., Foekens,J.A., Schneider,A., Schmalix,W., Haemers,A. and Augustyns,K.
    Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties
    J Med Chem50, 6638-6646. PubMed  Europe PubMed DOI  I
  120. [YEAR:29-1-2007]Killeen,S.D., Andrews,E.J., Wang,J.H., Wu,T., Schmalix,W., Muehlenweg,B. and Redmond,H.P.
    Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases
    Br J Cancer96, 262-268. PubMed  Europe PubMed DOI  I
  121. Pesaresi,M., Batelli,S., Prato,F., Polito,L., Lovati,C., Scarpini,E., Quadri,P., Mariani,C., Albani,D. and Forloni,G.
    The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level
    Neurobiol Dis25, 609-613. PubMed  Europe PubMed DOI  M
  122. [YEAR:1-2-2007]Pulukuri,S.M., Estes,N., Patel,J. and Rao,J.S.
    Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer
    Cancer Res67, 930-939. PubMed  Europe PubMed DOI
  123. Salvi,A., Arici,B., Alghisi,A., Barlati,S. and De Petro,G.
    RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice
    Tumour Biol28, 16-26. PubMed  Europe PubMed DOI
  124. [YEAR:28-1-2007]Stillfried,G.E., Saunders,D.N. and Ranson,M.
    Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity
    Breast Cancer Res9, R14-R14. PubMed  Europe PubMed DOI
  125. Traktuev,D.O., Tsokolaeva,Z.I., Shevelev,A.A., Talitskiy,K.A., Stepanova,V.V., Johnstone,B.H., Rahmat-Zade,T.M., Kapustin,A.N., Tkachuk,V.A., March,K.L. and Parfyonova,Y.V.
    Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle
    Mol Ther15, 1939-1946. PubMed  Europe PubMed DOI
  126. Zhao,G., Yuan,C., Wind,T., Huang,Z., Andreasen,P.A. and Huang,M.
    Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1
    J Struct Biol160, 1-10. PubMed  Europe PubMed DOI  S  I
    127. 2006
  127. Abi-Habib,R.J., Singh,R., Liu,S., Bugge,T.H., Leppla,S.H. and Frankel,A.E.
    A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types
    Mol Cancer Ther5, 2556-2562. PubMed  Europe PubMed DOI
  128. [YEAR:28-7-2006]Bansal,V. and Roychoudhury,P.K.
    Production and purification of urokinase: a comprehensive review
    Protein Expr Purif45, 1-14. PubMed  Europe PubMed DOI  V
  129. [YEAR:26-7-2006]Chung,D.E. and Kratz,F.
    Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA)
    Bioorg Med Chem Lett16, 5157-5163. PubMed  Europe PubMed DOI
  130. Gonzalez-Cuevas,J., Bueno-Topete,M. and Armendariz-Borunda,J.
    Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue
    J Gastroenterol Hepatol21, 1544-1554. PubMed  Europe PubMed DOI
  131. Gossage,J.A., Humphries,J., Modarai,B., Burnand,K.G. and Smith,A.
    Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution
    J Vasc Surg44, 1085-1090. PubMed  Europe PubMed DOI  U
  132. [YEAR:8-2-2006]Heynekamp,J.J., Hunsaker,L.A., Vander Jagt,T.A., Deck,L.M. and Vander Jagt,D.L.
    Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
    BMC Chem Biol6, 1-1. PubMed  Europe PubMed DOI  I
  133. [YEAR:21-9-2006]Joossens,J., Van der Veken,P., Surpateanu,G., Lambeir,A.M., El-Sayed,I., Ali,O.M., Augustyns,K. and Haemers,A.
    Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position
    J Med Chem49, 5785-5793. PubMed  Europe PubMed DOI  I
  134. [YEAR:22-6-2006]Kilpatrick,L.M., Harris,R.L., Owen,K.A., Bass,R., Ghorayeb,C., Bar-Or,A. and Ellis,V.
    Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase
    Blood108, 2616-2623. PubMed  Europe PubMed DOI
  135. [YEAR:6-2-2006]Lin,J., Yang,X., Deng,R., Yu,B., Lai,H., Sun,W. and Wu,W.
    Soluble expression of a strong thrombolytic pro-urokinase mutant in Escherichia coli
    Protein Expr Purif48, 69-73. PubMed  Europe PubMed DOI  E
  136. Margheri,F., Manetti,M., Serrati,S., Nosi,D., Pucci,M., Matucci-Cerinic,M., Kahaleh,B., Bazzichi,L., Fibbi,G., Ibba-Manneschi,L. and Del Rosso,M.
    Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells
    Arthritis Rheum54, 3926-3938. PubMed  Europe PubMed DOI
  137. [YEAR:6-7-2006]Riemenschneider,M., Konta,L., Friedrich,P., Schwarz,S., Taddei,K., Neff,F., Padovani,A., Kolsch,H., Laws,S.M., Klopp,N., Bickeboller,H., Wagenpfeil,S., Mueller,J.C., Rosenberger,A., Diehl-Schmid,J., Archetti,S., Lautenschlager,N., Borroni,B., Muller,U., Illig,T., Heun,R., Egensperger,R., Schlegel,J., Forstl,H., Martins,R.N. and Kurz,A.
    A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease
    Hum Mol Genet15, 2446-2456. PubMed  Europe PubMed DOI
  138. [YEAR:17-3-2006]Sienczyk,M. and Oleksyszyn,J.
    Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: The influence of the ester group on their biological activity
    Bioorg Med Chem Lett16, 2886-2890. PubMed  Europe PubMed DOI  I
  139. Zhao,G.X., Yuan,C., Bian,C.B., Jiang,L.G., Ye,X.M., Huang,Z.X. and Huang,M.D.
    Expression, purification and crystallization of urokinase catalytic domain in Pichia pastoris
    Prog Biochem Biophys33, 377-381.  E
    140. 2005
  140. [YEAR:7-10-2005]Almholt,K., Lund,L.R., Rygaard,J., Nielsen,B.S., Dano,K., Romer,J. and Johnsen,M.
    Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice
    Int J Cancer113, 525-532. PubMed  Europe PubMed DOI  K
  141. Bruncko,M., McClellan,W.J., Wendt,M.D., Sauer,D.R., Geyer,A., Dalton,C.R., Kaminski,M.A., Weitzberg,M., Gong,J., Dellaria,J.F., Mantei,R., Zhao,X., Nienaber,V.L., Stewart,K., Klinghofer,V., Bouska,J., Rockway,T.W. and Giranda,V.L.
    Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties
    Bioorg Med Chem Lett15, 93-98. PubMed  Europe PubMed DOI  I
  142. Hansen,M., Wind,T., Blouse,G.E., Christensen,A., Petersen,H.H., Kjelgaard,S., Mathiasen,L., Holtet,T.L. and Andreasen,P.A.
    A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition
    J Biol Chem280, 38424-38437. PubMed  Europe PubMed DOI  I
  143. [YEAR:1-8-2005]Jin,T., Bokarewa,M. and Tarkowski,A.
    Urokinase-type plasminogen activator, an endogenous antibiotic
    J Infect Dis192, 429-437. PubMed  Europe PubMed DOI
  144. [YEAR:12-11-2005]Katsuta,Y., Yoshida,Y., Kawai,E., Suetsugu,M., Kohno,Y., Inomata,S. and Kitamura,K.
    trans-4-(Aminomethyl)cyclohexane carboxylic acid methylamide (t-AMCHA methylamide) inhibits the physical interaction between urokinase-type plasminogen activator and stratum corneum, and accelerates the recovery of barrier function
    J Dermatol Sci40, 218-220. PubMed  Europe PubMed DOI  I
  145. Setyono-Han,B., Sturzebecher,J., Schmalix,W.A., Muehlenweg,B., Sieuwerts,A.M., Timmermans,M., Magdolen,V., Schmitt,M., Klijn,J.G. and Foekens,J.A.
    Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1
    Thromb Haemost93, 779-786. PubMed  Europe PubMed DOI  I
  146. [YEAR:12-11-2005]Wang,X., Hou,M., Tan,L., Sun,X., Zhang,Y., Li,P. and Zhu,Y.
    A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis
    J Cancer Res Clin Oncol131, 129-136. PubMed  Europe PubMed DOI
  147. Yu,Y.S., Zhou,Y.R., Lu,J.S., Wu,X.J., Li,Q.W. and Deng,J.X.
    [The construction and characterization of human pro-urokinase mutant]
    Sheng Wu Gong Cheng Xue Bao21, 573-578. PubMed  Europe PubMed  E
    148. 2004
  148. [YEAR:21-6-2004]Barber,C.G., Dickinson,R.P. and Fish,P.V.
    Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines
    Bioorg Med Chem Lett14, 3227-3230. PubMed  Europe PubMed DOI  I
  149. Ellis,V.
    u-Plasminogen activator
    [ISSN:0-12-079610-4]2, 1677-1683.  V
  150. [YEAR:6-5-2004]Joossens,J., Van der Veken,P., Lambeir,A.M., Augustyns,K. and Haemers,A.
    Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator
    J Med Chem47, 2411-2413. PubMed  Europe PubMed DOI  I
  151. [YEAR:19-11-2004]Katz,B.A., Luong,C., Ho,J.D., Somoza,J.R., Gjerstad,E., Tang,J., Williams,S.R., Verner,E., Mackman,R.L., Young,W.B., Sprengeler,P.A., Chan,H., Mortara,K., Janc,J.W. and McGrath,M.E.
    Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA)
    J Mol Biol344, 527-547. PubMed  Europe PubMed DOI  I
  152. [YEAR:18-5-2004]Schweinitz,A., Steinmetzer,T., Banke,I.J., Arlt,M.J., Sturzebecher,A., Schuster,O., Geissler,A., Giersiefen,H., Zeslawska,E., Jacob,U., Kruger,A. and Sturzebecher,J.
    Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents
    J Biol Chem279, 33613-33622. PubMed  Europe PubMed DOI  I
  153. Tanski,W.J., Fegley,A.J., Roztocil,E. and Davies,M.G.
    Domain-dependent action of urokinase on smooth muscle cell responses
    J Vasc Surg39, 214-222. PubMed  Europe PubMed DOI
  154. [YEAR:15-1-2004]Wendt,M.D., Rockway,T.W., Geyer,A., McClellan,W., Weitzberg,M., Zhao,X., Mantei,R., Nienaber,V.L., Stewart,K., Klinghofer,V. and Giranda,V.L.
    Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution
    J Med Chem47, 303-324. PubMed  Europe PubMed DOI  I
  155. Wendt,M.D., Geyer,A., McClellan,W.J., Rockway,T.W., Weitzberg,M., Zhao,X., Mantei,R., Stewart,K., Nienaber,V., Klinghofer,V. and Giranda,V.L.
    Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors
    Bioorg Med Chem Lett14, 3063-3068. PubMed  Europe PubMed DOI  S  I
    156. 2003
  156. Aimes,R.T., Regazzoni,K. and Quigley,J.P.
    Human/chicken urokinase chimeras demonstrate sequences outside the serine protease domain that dictate autoactivation
    Thromb Haemost89, 382-392. PubMed  Europe PubMed DOI
  157. [YEAR:15-4-2003]Behrendt,N., List,K., Andreasen,P.A. and Dano,K.
    The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation
    Biochem J371, 277-287. PubMed  Europe PubMed DOI
  158. Beqaj,S.H., Post,D. and Ryan,J.M.
    Single-nucleotide polymorphism of the urokinase-plasminogen activator gene during aging and transformation of human diploid kidney cell cultures
    In Vitro Cell Dev Biol Anim39, 343-347. PubMed  Europe PubMed DOI  M
  159. Daci,E., Everts,V., Torrekens,S., Van Herck,E., Tigchelaar-Gutterr,W., Bouillon,R. and Carmeliet,G.
    Increased bone formation in mice lacking plasminogen activators
    J Bone Miner Res18, 1167-1176. PubMed  Europe PubMed DOI  K
  160. Rakic,J.M., Maillard,C., Jost,M., Bajou,K., Masson,V., Devy,L., Lambert,V., Foidart,J.M. and Noel,A.
    Role of plasminogen activator-plasmin system in tumor angiogenesis
    Cell Mol Life Sci60, 463-473. PubMed  Europe PubMed DOI
  161. [YEAR:18-4-2003]Zeslawska,E., Jacob,U., Schweinitz,A., Coombs,G., Bode,W. and Madison,E.
    Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors
    J Mol Biol328, 109-118. PubMed  Europe PubMed DOI  S  I
    162. 2002
  162. Artym,V.V., Kindzelskii,A.L., Chen,W.T. and Petty,H.R.
    Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton
    Carcinogenesis23, 1593-1601. PubMed  Europe PubMed
  163. [YEAR:21-1-2002]Barber,C.G., Dickinson,R.P. and Horne,V.A.
    Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-pyridinylguanidines
    Bioorg Med Chem Lett12, 181-184. PubMed  Europe PubMed DOI  I
  164. [YEAR:21-1-2002]Barber,C.G. and Dickinson,R.P.
    Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-substituted-5-halo-2-pyridinyl)guanidines
    Bioorg Med Chem Lett12, 185-187. PubMed  Europe PubMed DOI  I
  165. [YEAR:6-12-2002]Crisp,R.J., Knauer,M.F. and Knauer,D.J.
    Protease nexin 1 is a potent urinary plasminogen activator inhibitor in the presence of collagen type IV
    J Biol Chem277, 47285-47291. PubMed  Europe PubMed DOI
  166. [YEAR:5-8-2002]Mackman,R.L., Hui,H.C., Breitenbucher,J.G., Katz,B.A., Luong,C., Martelli,A., McGee,D., Radika,K., Sendzik,M., Spencer,J.R., Sprengeler,P.A., Tario,J., Verner,E. and Wang,J.
    2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors
    Bioorg Med Chem Lett12, 2019-2022. PubMed  Europe PubMed DOI  I
  167. Sisson,T.H., Hanson,K.E., Subbotina,N., Patwardhan,A., Hattori,N. and Simon,R.H.
    Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice
    Am J Physiol Lung Cell Mol Physiol283, L1023-L1032. PubMed  Europe PubMed DOI
  168. [YEAR:5-8-2002]Spencer,J.R., McGee,D., Allen,D., Katz,B.A., Luong,C., Sendzik,M., Squires,N. and Mackman,R.L.
    4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors
    Bioorg Med Chem Lett12, 2023-2026. PubMed  Europe PubMed DOI  I
  169. [YEAR:15-4-2002]Sun,Z., Zhang,P.X., Wang,P., Gurewich,V., Shen,H.Y. and Liu,J.N.
    Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation
    Thromb Res106, 105-111. PubMed  Europe PubMed DOI
    170. 2001
  170. Jiao,J.W., Yu,M.M. and Ru,B.G.
    Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase
    Biochimie83, 1049-1055. PubMed  Europe PubMed DOI
  171. [YEAR:15-7-2001]Kahr,W.H.A., Zheng,S.L., Sheth,P.M., Pai,M., Cowie,A., Bouchard,M., Podor,T.J., Rivard,G.E. and Hayward,C.P.M.
    Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator
    Blood98, 257-265. PubMed  Europe PubMed DOI  K
  172. Katz,B.A., Sprengeler,P.A., Luong,C., Verner,E., Elrod,K., Kirtley,M., Janc,J., Spencer,J.R., Breitenbucher,J.G., Hui,H., McGee,D., Allen,D., Martelli,A. and Mackman,R.L.
    Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets
    Chem Biol8, 1107-1121. PubMed  Europe PubMed DOI  S
  173. [YEAR:7-8-2001]Klinghofer,V., Stewart,K., McGonigal,T., Smith,R., Sarthy,A., Nienaber,V., Butler,C., Dorwin,S., Richardson,P., Weitzberg,M., Wendt,M., Rockway,T., Zhao,X.M., Hulkower,K.I. and Giranda,V.L.
    Species specificity of amidine-based urokinase inhibitors
    Biochemistry40, 9125-9131. PubMed  Europe PubMed DOI  I
  174. Shimizu,M., Hara,A., Okuno,M., Matsuno,H., Okada,K., Ueshima,S., Matsuo,O., Niwa,M., Akita,K., Yamada,Y., Yoshimi,N., Uematsu,T., Kojima,S., Friedman,S.L., Moriwaki,H. and Mori,H.
    Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: Impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis
    Hepatology33, 569-576. PubMed  Europe PubMed DOI
  175. [YEAR:4-6-2001]Subasinghe,N.L., Illig,C., Hoffman,J., Rudolph,M.J., Wilson,K.J., Soll,R., Randle,T., Green,D., Lewandowski,F., Zhang,M., Bone,R., Spurlino,J., DesJarlais,R., Deckman,I., Molloy,C.J., Manthey,C., Zhou,Z., Sharp,C., Maguire,D., Crysler,C. and Grasberger,B.
    Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors
    Bioorg Med Chem Lett11, 1379-1382. PubMed  Europe PubMed DOI  I
  176. [YEAR:25-9-2001]Tirschwell,D.L., Coplin,W.M., Becker,K.J., Vogelzang,P., Eskridge,J., Haynor,D., Cohen,W., Newell,D., Winn,H.R. and Longstreth,W.T., Jr.
    Intra-arterial urokinase for acute ischemic stroke: Factors associated with complications
    Neurology57, 1100-1103. PubMed  Europe PubMed
  177. Vakili,J., Standker,L., Detheux,M., Vassart,G., Forssmann,W.G. and Parmentier,M.
    Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active [9-74] processed variant
    J Immunol167, 3406-3413. PubMed  Europe PubMed  P
    178. 2000
  178. [YEAR:20-9-2000]Braat,E.A., Collen,A., Jie,A.F., Grimbergen,J.M. and Rijken,D.C.
    The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells
    Biochim Biophys Acta1497, 351-358. PubMed  Europe PubMed DOI
  179. Floridon,C., Nielsen,O., Holund,B., Sweep,F., Sunde,L., Thomsen,S.G. and Teisner,B.
    Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies
    Placenta21, 754-762. PubMed  Europe PubMed DOI
  180. Hajduk,P.J., Boyd,S., Nettesheim,D., Nienaber,V., Severin,J., Smith,R., Davidson,D., Rockway,T. and Fesik,S.W.
    Identification of novel inhibitors of urokinase via NMR-based screening
    J Med Chem43, 3862-3866. PubMed  Europe PubMed DOI  I
  181. [YEAR:5-7-2000]Harris,J.L., Backes,B.J., Leonetti,F., Mahrus,S., Ellman,J.A. and Craik,C.S.
    Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries
    Proc Natl Acad Sci U S A97, 7754-7759. PubMed  Europe PubMed DOI  P
  182. Katz,B.A., Mackman,R., Luong,C., Radika,K., Martelli,A., Sprengeler,P.A., Wang,J., Chan,H. and Wong,L.
    Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator
    Chem Biol7, 299-312. PubMed  Europe PubMed DOI  S
  183. [YEAR:10-3-2000]Nienaber,V., Wang,J., Davidson,D. and Henkin,J.
    Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite
    J Biol Chem275, 7239-7248. PubMed  Europe PubMed DOI  S
  184. [YEAR:15-5-2000]Nienaber,V.L., Davidson,D., Edalji,R., Giranda,V.L., Klinghofer,V., Henkin,J., Magdalinos,P., Mantei,R., Merrick,S., Severin,J.M., Smith,R.A., Stewart,K., Walter,K., Wang,J., Wendt,M., Weitzberg,M., Zhao,X. and Rockway,T.
    Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite
    Structure8, 553-563. PubMed  Europe PubMed DOI  I
  185. [YEAR:11-8-2000]Zeslawska,E., Schweinitz,A., Karcher,A., Sondermann,P., Sperl,S., Sturzebecher,J. and Jacob,U.
    Crystals of the urokinase type plasminogen activator variant beta(c)-uPA in complex with small molecule inhibitors open the way towards structure-based drug design
    J Mol Biol301, 465-475. PubMed  Europe PubMed DOI  S  I
  186. [YEAR:1-9-2000]Zhou,H.M., Nichols,A., Meda,P. and Vassalli,J.D.
    Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis
    EMBO J19, 4817-4826. PubMed  Europe PubMed DOI
    187. 1999
  187. Bhat,G.J., Gunaje,J.J. and Idell,S.
    Urokinase-type plasminogen activator induces tyrosine phosphorylation of a 78-kDa protein in H-157 cells
    Am J Physiol277, L301-L309. PubMed  Europe PubMed
  188. Braat,E.A., Levi,M., Bos,R., Haverkate,F., Lassen,M.R., de Maat,M.P. and Rijken,D.C.
    Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects
    J Lab Clin Med134, 161-167. PubMed  Europe PubMed DOI
  189. [YEAR:12-1-1999]Ellis,V., Whawell,S.A., Werner,F. and Deadman,J.J.
    Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen
    Biochemistry38, 651-659. PubMed  Europe PubMed DOI
  190. [YEAR:1-11-1999]Sturzebecher,J., Vieweg,H., Steinmetzer,T., Schweinitz,A., Stubbs,M.T., Renatus,M. and Wikstrom,P.
    3-amidinophenylalanine-based inhibitors of urokinase
    Bioorg Med Chem Lett9, 3147-3152. PubMed  Europe PubMed DOI  I
    191. 1998
  191. Sugiki,M., Yoshida,E., Anai,K. and Maruyama,M.
    Activation of single-chain urokinase-type plasminogen activator by a hemorrhagic metalloproteinase, jararafibrase I, in Bothrops jararaca venom
    Toxicon36, 993-1000. PubMed  Europe PubMed DOI
  192. [YEAR:19-5-1998]Ugwu,F., Van Hoef,B., Bini,A., Collen,D. and Lijnen,H.R.
    Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3)
    Biochemistry37, 7231-7236. PubMed  Europe PubMed DOI
    193. 1997
  193. Jackson,T.P., Cooper,S.T. and Church,F.C.
    Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor
    J Protein Chem16, 819-828. PubMed  Europe PubMed DOI
  194. Ke,S.H., Coombs,G.S., Tachias,K., Navre,M., Corey,D.R. and Madison,E.L.
    Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase
    J Biol Chem272, 16603-16609. PubMed  Europe PubMed DOI  P
  195. Ke,S.H., Coombs,G.S., Tachias,K., Navre,M., Corey,D.R. and Madison,E.L.
    Distinguishing the specificities of closely related proteases: role of p3 in substrate and inhibitor discrimination between tissue type plasminogen activator and urokinase
    Fibrinolysis Proteolysis11 Suppl. 3, 51-51.  P
  196. Monzon-Bordonaba,F., Wang,C.L. and Feinberg,R.F.
    Fibronectinase activity in cultured human trophoblasts is mediated by urokinase-type plasminogen activator
    Am J Obstet Gynecol176, 58-65. PubMed  Europe PubMed
  197. Shapiro,R.L., Duquette,J.G., Nunes,I., Roses,D.F., Harris,M.N., Wilson,E.L. and Rifkin,D.B.
    Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles
    Am J Pathol150, 359-369. PubMed  Europe PubMed  K
  198. Sipley,J.D., Alexander,D.S., Testa,J.E., Mueller,B. and Quigley,J.P.
    Chicken plasminogen activator (chupa): autoactivating and serpin resistant: a protease out of control
    Fibrinolysis Proteolysis11 Suppl. 3, 45-45.
    199. 1996
  199. Higazi,A.a. and Cines,D.
    Regulation of single chain urokinase by small peptides
    Thromb Res84, 243-252. PubMed  Europe PubMed DOI
  200. Lijnen,H.R., Van Hoef,B. and Collen,D.
    Characterization of the murine plasminogen/urokinase-type plasminogen-activator system
    Eur J Biochem241, 840-848. PubMed  Europe PubMed
    201. 1995
  201. [YEAR:3-10-1995]Ploug,M., Rahbek-Nielsen,H., Ellis,V., Roepstorff,P. and Dano,K.
    Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction
    Biochemistry34, 12524-12534. PubMed  Europe PubMed
  202. Spraggon,G., Phillips,C., Nowak,U.K., Ponting,C.P., Saunders,D., Dobson,C.M., Stuart,D.I. and Jones,E.Y.
    The crystal structure of the catalytic domain of human urokinase-type plasminogen activator
    Structure3, 681-691. PubMed  Europe PubMed  S
  203. Wilhelm,O., Schmitt,M., Hohl,S., Senekowitsch,R. and Graeff,H.
    Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice
    Clin Exp Metastasis13, 296-302. PubMed  Europe PubMed DOI  K
    204. 1994
  204. Carmeliet,P., Schoonjans,L., Kieckens,L., Ream,B., Degen,J., Bronson,R., De Vos,R., van den Oord,J.J., Collen,D. and Mulligan,R.C.
    Physiological consequences of loss of plasminogen activator gene function in mice
    Nature368, 419-424. PubMed  Europe PubMed DOI  K
  205. [YEAR:15-7-1994]Nauland,U. and Rijken,D.C.
    Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C)
    Eur J Biochem223, 497-501. PubMed  Europe PubMed DOI
    206. 1993
  206. [YEAR:5-9-1993]Fleury,V., Lijnen,H.R. and Angles-Cano,E.
    Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis
    J Biol Chem268, 18554-18559. PubMed  Europe PubMed
    207. 1992
  207. [YEAR:15-7-1992]Marcotte,P.A., Kozan,I.M., Dorwin,S.A. and Ryan,J.M.
    The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells
    J Biol Chem267, 13803-13806. PubMed  Europe PubMed
  208. Naldini,L., Tamagnone,L., Vigna,E., Sachs,M., Hartmann,G., Birchmeier,W., Daikuhara,Y., Tsubouchi,H., Blasi,F. and Comoglio,P.M.
    Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
    EMBO J11, 4825-4833. PubMed  Europe PubMed
  209. Schnyder,J., Marti,R., Cooper,P.H. and Payne,T.G.
    Spectrophotometric method to quantify and discriminate urokinase and tissue-type plasminogen activators
    Anal Biochem200, 156-162. PubMed  Europe PubMed  A
    210. 1991
  210. Kobayashi,H., Schmitt,M., Goretzki,L., Chucholowski,N., Calvete,J., Kramer,M., Gunzler,W.A., Janicke,F. and Graeff,H.
    Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA)
    J Biol Chem266, 5147-5152. PubMed  Europe PubMed
    211. 1990
  211. Avgerinos,G.C., Drapeau,D., Socolow,J.S., Mao,J.I., Hsiao,K. and Broeze,R.J.
    Spin filter perfusion system for high density cell culture: production of recombinant urinary type plasminogen activator in CHO cells
    Biotechnology (N Y)8, 54-58. PubMed  Europe PubMed DOI
  212. [YEAR:30-11-1990]Gaffney,P.J. and Heath,A.B.
    A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA)
    Thromb Haemost64, 398-401. PubMed  Europe PubMed
  213. Lijnen,H.R., Van Hoef,B., Nelles,L. and Collen,D.
    Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740->Ala) and plasmin-resistant scu- PA (Lys158->Glu)
    J Biol Chem265, 5232-5236. PubMed  Europe PubMed
  214. [YEAR:15-1-1990]Melnick,L.M., Turner,B.G., Puma,P., Price-Tillotson,B., Salvato,K.A., Dumais,D.R., Moir,D.T., Broeze,R.J. and Avgerinos,G.C.
    Characterization of a nonglycosylated single chain urinary plasminogen activator secreted from yeast
    J Biol Chem265, 801-807. PubMed  Europe PubMed
    215. 1989
  215. [YEAR:15-5-1989]Lijnen,H.R., Van Hoef,B., De Cock,F. and Collen,D.
    The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro
    Blood73, 1864-1872. PubMed  Europe PubMed
    216. 1987
  216. [YEAR:15-12-1987]Degen,S.J., Heckel,J.L., Reich,E. and Degen,J.L.
    The murine urokinase-type plasminogen activator gene
    Biochemistry26, 8270-8279. PubMed  Europe PubMed
  217. [YEAR:5-11-1987]Ellis,V., Scully,M.F. and Kakkar,V.V.
    Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study
    J Biol Chem262, 14998-15003. PubMed  Europe PubMed
  218. [YEAR:25-4-1987]Nelles,L., Lijnen,H.R., Collen,D. and Holmes,W.E.
    Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158
    J Biol Chem262, 5682-5689. PubMed  Europe PubMed
  219. Pannell,R. and Gurewich,V.
    Activation of plasminogen by single-chain urokinase or by two-chain urokinase - a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase)
    Blood69, 22-26. PubMed  Europe PubMed
  220. [YEAR:6-4-1987]Vassalli,J.D. and Belin,D.
    Amiloride selectively inhibits the urokinase-type plasminogen activator
    FEBS Lett214, 187-191. PubMed  Europe PubMed
    221. 1986
  221. [YEAR:25-1-1986]Collen,D., Zamarron,C., Lijnen,H.R. and Hoylaerts,M.
    Activation of plasminogen by pro-urokinase. II. Kinetics
    J Biol Chem261, 1259-1266. PubMed  Europe PubMed
  222. [YEAR:25-1-1986]Lijnen,H.R., Zamarron,C., Blaber,M., Winkler,M.E. and Collen,D.
    Activation of plasminogen by pro-urokinase. I. Mechanism
    J Biol Chem261, 1253-1258. PubMed  Europe PubMed
  223. [YEAR:15-7-1986]Winkler,M.E. and Blaber,M.
    Purification and characterization of recombinant single-chain urokinase produced in Escherichia coli
    Biochemistry25, 4041-4045. PubMed  Europe PubMed
    224. 1984
  224. Larsson,L.I., Skriver,L., Nielsen,L.S., Grondahl-Hansen,J., Kristensen,P. and Dano,K.
    Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
    J Cell Biol98, 894-903. PubMed  Europe PubMed
  225. [YEAR:1-6-1984]Lijnen,H.R., Uytterhoeven,M. and Collen,D.
    Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones
    Thromb Res34, 431-437. PubMed  Europe PubMed  I
    226. 1982
  226. Gunzler,W.A., Steffens,G.J., Otting,F., Kim,S.M., Frankus,E. and Flohe,L.
    The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain
    Hoppe Seylers Z Physiol Chem363, 1155-1165. PubMed  Europe PubMed
  227. [YEAR:26-2-1982]Samama,M., Castel,M., Matsuo,O., Hoylaerts,M. and Lijnen,H.R.
    Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin
    Thromb Haemost47, 36-40. PubMed  Europe PubMed
  228. [YEAR:17-5-1982]Skriver,L., Nielsen,L.S., Stephens,R. and Dano,K.
    Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus
    Eur J Biochem124, 409-414. PubMed  Europe PubMed
  229. Steffens,G.J., Gunzler,W.A., Otting,F., Frankus,E. and Flohe,L.
    The complete amino acid sequence of low molecular mass urokinase from human urine
    Hoppe Seylers Z Physiol Chem363, 1043-1058. PubMed  Europe PubMed
  230. [YEAR:25-3-1982]Wun,T.C., Schleuning,W.D. and Reich,E.
    Isolation and characterization of urokinase from human plasma
    J Biol Chem257, 3276-3283. PubMed  Europe PubMed
    231. 1981
  231. Lottenberg,R., Christensen,U., Jackson,C.M. and Colemen,P.L.
    Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates
    Methods Enzymol80, 341-361. PubMed  Europe PubMed DOI  V
  232. [YEAR:30-6-1981]Matsuo,O., Rijken,D.C. and Collen,D.
    Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro
    Thromb Haemost45, 225-229. PubMed  Europe PubMed
    233. 1979
  233. Astedt,B., Holmberg,L., Wagner,G., Richter,P. and Ploug,J.
    Purification of urokinase by a beta-naphthamidine affinity column
    Thromb Haemost42, 924-928. PubMed  Europe PubMed
  234. Quigley,J.P.
    Phorbol ester-induced morphological changes in transformed chick fibroblasts: evidence for direct catalytic involvement of plasmingen activator
    Cell17, 131-141. PubMed  Europe PubMed
    235. 1977
  235. Astedt,B., Bladh,B. and Holmberg,L.
    Some characteristics of urokinase released in organ culture of human kidney
    Experientia33, 589-591. PubMed  Europe PubMed
  236. Morita,T., Kato,H., Iwanaga,S., Takada,K., Kimura,T. and Sakakibara,S.
    New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase
    J Biochem82, 1495-1498. PubMed  Europe PubMed  A
    237. 1976
  237. Holmberg,L., Bladh,B. and Astedt,B.
    Purification of urokinase by affinity chromatography
    Biochim Biophys Acta445, 215-222. PubMed  Europe PubMed
    238. 1974
  238. Thorsen,S. and Astrup,T.
    Substrate composition and the effect of úomegaú-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis
    Thromb Diath Haemorrh32, 306-324. PubMed  Europe PubMed  I
    239. 1970
  239. Landmann,H. and Markwardt,F.
    [Irreversible synthetic inhibitors of urokinase]
    Experientia26, 145-147. PubMed  Europe PubMed DOI  I
    240. 1969
  240. Kok,P. and Astrup,T.
    Isolation and purification of a tissue plasminogen activator and its comparison with urokinase
    Biochemistry8, 79-86. PubMed  Europe PubMed
    241. 1967
  241. Robbins,K.C., Summaria,L., Hsieh,B. and Shah,R.J.
    The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin
    J Biol Chem242, 2333-2342. PubMed  Europe PubMed
    242. 1965
  242. Lorand,L. and Condit,E.V.
    Ester hydrolysis by urokinase
    Biochemistry4, 265-270.
    243. 1957
  243. Kjeldgaard,N.O. and Ploug,J.
    Urokinase an activator of plasminogen from human urine. II. Mechanism of plasminogen activation
    Biochim Biophys Acta24, 283-289. PubMed  Europe PubMed
  244. Ploug,J. and Kjeldgaard,N.O.
    Urokinase an activator of plasminogen from human urine. I. Isolation and properties
    Biochim Biophys Acta24, 278-282. PubMed  Europe PubMed
    245. 1952
  245. Astrup,T. and Stage,A.
    Isolation of a soluble fibrinolytic activator from animal tissue
    Nature170, 929ab9- PubMed  Europe PubMed DOI
    246. 1951
  246. Astrup,T.
    Fibrinokinase
    Acta Physiol Scand24, 267-277. PubMed  Europe PubMed DOI
    247. 1948
  247. Astrup,T. and Permin,P.M.
    Fibrinokinase and fibrinolytic enzymes
    Nature161, 689-690. PubMed  Europe PubMed
    248. 1947
  248. Astrup,T. and Permin,P.M.
    Fibrinolysis in the animal organism
    Nature159, 681-682. PubMed  Europe PubMed

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use